Targets › PDK3
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Oncology.
Inhibits pyruvate dehydrogenase activity by phosphorylation of the E1 subunit PDHA1, and thereby regulates glucose metabolism and aerobic respiration. Can also phosphorylate PDHA2. (UniProt, Q15120)
Open in Phaseline: the race on PDK3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Saol Therapeutics | Sodium Dichloroacetate Pyruvate dehydrogenase kinase inhibitor | PDK2, PDK3, PDK4, PDK1 | Phase 3 | Pyruvate Dehydrogenase Complex Deficiency; Glioblastoma Multiforme | – |
Pyruvate Dehydrogenase Complex Deficiency (1) Glioblastoma Multiforme (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.